new glp 1 med GLP-1 Weight Loss Options Novo Nordisk | The first

Diabetes, obesity & metabolism , 27 Suppl 2 (Suppl 2), 6688.

Patients should seek immediate medical attention for severe persistent abdominal pain (possible pancreatitis), right upper quadrant pain with fever (possible gallbladder disease), severe vomiting leading to dehydration, decreased urine output (possible acute kidney injury), or significant vision changes (possible diabetic retinopathy complications)

The FDA objected Friday, and Novo Nordisk sued for patent infringement this morning

Fadini Gian P, Frison V, Simioni N, et al

Please enter a valid emailAn error has occurred, please try again later GPhC number 9012073

doi: 10.1152/ajpendo.1996.270.4.E661